Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034066 | 0.84 | MAPKAPK2 (0.41) | MAPKAPK2ABCB1ABCG2LMNATP53 | |
| SCHEMBL2030178 | 0.83 | MAPKAPK2 (0.43) | MAPKAPK2ABCG2KIF11HSD17B10KDM4E | |
| SCHEMBL2029583 | 0.82 | ELANE (0.36) | MAPKAPK2ABCB1ABCG2 | |
| SCHEMBL2031420 | 0.80 | MAPKAPK2 (0.41) | MAPKAPK2ABCB1ABCG2LMNAHSD17B10 | |
| SCHEMBL2030005 | 0.80 | KIF11 (0.42) | MAPKAPK2ABCB1ABCG2LMNAKIF11 | |
| SCHEMBL2034677 | 0.80 | MAPKAPK2 (0.40) | MAPKAPK2ABCB1ABCG2LMNAKIF11 | |
| SCHEMBL2029776 | 0.80 | NPSR1 (0.42) | MAPKAPK2ABCB1ABCG2LMNAALDH1A1 | |
| SCHEMBL2031707 | 0.80 | MAPKAPK2 (0.40) | MAPKAPK2LMNATP53KIF11HSD17B10 | |
| SCHEMBL2031494 | 0.79 | MAPKAPK2 (0.40) | MAPKAPK2ABCB1ABCG2LMNAKIF11 | |
| SCHEMBL2031468 | 0.79 | ABCB1 (0.42) | ABCB1ABCG2KIF11HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | US | claimed |
| US-8952158-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | claimed |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | claimed |
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | claimed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | claimed |
| EP-1829874-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8952158-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8476293-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-7964726-B2 | 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1829874-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | MAPKAPK2 3947/4885ABCB1 90/4885ABCG2 265/4885 |
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | MAPKAPK2 3947/4885ABCB1 90/4885ABCG2 265/4885 |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | MAPKAPK2 3947/4885ABCB1 90/4885ABCG2 265/4885 |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | SI, ALPI, SLC10A2 | MAPKAPK2 3971/4885ABCB1 97/4885ABCG2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.